Dragon Pharma Sibutramine 20mg Appetite Control Tablets

Sibutramine 20 mg by Dragon Pharma contains pharmaceutical-grade Sibutramine Hydrochloride, a potent centrally acting appetite suppressant designed to assist research involving weight management, caloric reduction, metabolic enhancement, and appetite control. Classified as a norepinephrine, serotonin, and dopamine reuptake inhibitor (NSDRI), Sibutramine supports energy expenditure and reduced hunger signals, making it highly relevant in studies on obesity, metabolic disorders, and body recomposition.

What It Is

Sibutramine is an oral anorectic agent originally marketed under the brand name Meridia. It functions as a triple reuptake inhibitor, increasing levels of norepinephrine and serotonin to reduce appetite and enhance satiety. Researchers use Sibutramine in metabolic studies, appetite-suppression protocols, and obesity-related research to evaluate its impact on thermogenesis, caloric intake, and weight-loss mechanisms.

How It Works

Sibutramine selectively inhibits the reuptake of norepinephrine, serotonin, and dopamine, increasing availability of these neurotransmitters in synaptic clefts. This results in:

• Reduced appetite due to enhanced satiety signaling in the hypothalamus.
• Increased thermogenesis through sympathetic nervous system stimulation.
• Improved metabolic rate and greater caloric expenditure.

Additionally, Sibutramine may elevate resting energy expenditure, making it effective for research exploring weight-loss dynamics and metabolic control.

Sibutramine 20mg Benefits

• Appetite Suppression: Reduces cravings and frequency of eating.
• Enhanced Satiety: Promotes fullness and controlled caloric intake.
• Metabolic Boost: Increases thermogenesis and resting energy expenditure.
• Weight Management: Supports caloric deficit studies and recomposition models.
• Improved Dietary Compliance: Helps maintain structured eating protocols.

Who It's For

Sibutramine is used in research involving obesity, appetite regulation, metabolic dysfunction, caloric restriction studies, and body recomposition. It is relevant in both short-term and long-term weight-management models. Not recommended for individuals with cardiovascular disease, hypertension, or arrhythmias due to potential stimulatory effects.

How to Use

Administration: Taken orally with water, with or without food.

Dosage: Common research doses range from 10–20 mg daily, with 20 mg used in advanced studies depending on response.

Timing: Typically administered in the morning to minimize sleep disruption.

Duration: Weight-loss studies commonly run 4–12 weeks, with ongoing monitoring of blood pressure and heart rate.

Stacking Suggestions

Sibutramine is often included in metabolic and weight-loss study stacks:

• Clenbuterol: For thermogenic synergy (monitor cardiovascular variables).
• T3/T4 thyroid: Enhances metabolic rate in obesity studies.
• Metformin: Improves insulin sensitivity and appetite regulation.

Avoid stacking with strong stimulants or MAOIs due to neurotransmitter interaction.

Side Effects

Potential side effects documented include:

• Increased heart rate
• Elevated blood pressure
• Dry mouth
• Headache
• Insomnia or restlessness

Rare but serious effects include tachyarrhythmia or cardiovascular stress—monitoring is essential in research environments.

Post Cycle Therapy (PCT)

Sibutramine does not impact testosterone or endocrine function, so PCT is not required. However, appetite rebound should be monitored if used in extended caloric-deficit studies.